All Stories

  1. Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models
  2. Alterations of RNA Metabolism by Proteomic Analysis of Breast Cancer Cells Exposed to Marycin: A New Optically Active Porphyrin
  3. Role of FoxO Proteins in Cellular Response to Antitumor Agents
  4. KiSS1 in regulation of metastasis and response to antitumor drugs
  5. Tau Mutations as a Novel Risk Factor for Cancer—Response
  6. Tau mutations serve as a novel risk factor for cancer
  7. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models
  8. Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group
  9. Molecular basis for the DNA damage induction and anticancer activity of asymmetrically substituted anthrapyridazone PDZ-7
  10. Editorial: Targeting Drug-resistant and Metastatic Tumors by Interference with Tumor and Microenvironment-related Alterations
  11. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells
  12. Integrin-targeted peptide- and peptidomimetic-drug conjugates for the treatment of tumors
  13. RECQL4 Modulates MDR1 Expression and Chemoresistance—Letter
  14. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells
  15. Synthetic sulfoglycolipids targeting the serine–threonine protein kinase Akt
  16. Axl in the invasive capability and drug resistance of tumor cells
  17. Targeting Peptidyl-Prolyl Isomerase Pin1 to Inhibit Tumor Cell Aggressiveness
  18. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy
  19. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis
  20. Orchestration of DSB repair: a novel BRCA2 connection
  21. New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants
  22. Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor
  23. Anionic glycolipids related to glucuronosyldiacylglycerol inhibit protein kinase Akt
  24. Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD–paclitaxel conjugates for integrin-assisted drug delivery
  25. Preface: Histone Deacetylases as Therapeutic Targets
  26. p53-Dependent Activation of microRNA-34a in Response to Etoposide-Induced DNA Damage in Osteosarcoma Cell Lines Not Impaired by Dominant Negative p53 Expression
  27. Nucleolar Targeting by Platinum: p53-Independent Apoptosis Follows rRNA Inhibition, Cell-Cycle Arrest, and DNA Compaction
  28. Association of promoter polymorphism −765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts
  29. Phosphatidylinositol 3-Phosphate Mimics Based on a Sulfoquinovose Scaffold: Synthesis and Evaluation as Protein Kinase B Inhibitors
  30. Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells
  31. Synergistic Cooperation Between Sunitinib and Cisplatin Promotes Apoptotic Cell Death in Human Medullary Thyroid Cancer
  32. 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors
  33. Improved Apoptotic Cell Death in Drug-Resistant Non–Small-Cell Lung Cancer Cells by Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Based Treatment
  34. Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity
  35. Drug Combinations with Proteasome Inhibitors in Antitumor Therapy
  36. Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
  37. Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug
  38. Synthesis and Biological Evaluation (in Vitro and in Vivo) of Cyclic Arginine–Glycine–Aspartate (RGD) Peptidomimetic–Paclitaxel Conjugates Targeting Integrin αVβ3
  39. Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis
  40. Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization
  41. Design, Synthesis, and Biological Evaluation of Novel cRGD–Paclitaxel Conjugates for Integrin-Assisted Drug Delivery
  42. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells
  43. Sensitization of tumor cells by targeting histone deacetylases
  44. Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
  45. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition
  46. Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
  47. Inhibition of proteasome deubiquitinating activity as a new cancer therapy
  48. Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
  49. Proteomic Analysis of Cellular Response to Novel Proapoptotic Agents Related to Atypical Retinoids in Human IGROV-1 Ovarian Carcinoma Cells
  50. Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast
  51. Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells
  52. Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine
  53. The ABC of glycosylation
  54. Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment
  55. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin
  56. Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN
  57. Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile
  58. Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment
  59. ABC Transporters as Potential Targets for Modulation of Drug Resistance
  60. Strategies to Improve the Efficacy of Platinum Compounds
  61. A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells
  62. Small Molecules Targeting p53 to Improve Antitumor Therapy
  63. Defining targets of modulation of human tumor cell response to cisplatin
  64. Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells
  65. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds
  66. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells
  67. Biological Properties of IDN5174, a New Synthetic Camptothecin with the Open Lactone Ring
  68. Mechanisms of Cellular Resistance to Camptothecins
  69. Modulation of cell growth and cisplatin sensitivity by membrane γ-glutamyltransferase in melanoma cells
  70. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells
  71. Cellular Sensitivity to β-Diketonato Complexes of Ruthenium(III), Chromium(III) and Rhodium(III)
  72. Molecular alterations of cells resistant to platinum drugs: Role of PKCα
  73. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts
  74. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431
  75. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors
  76. Global gene expression of fission yeast in response to cisplatin
  77. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells
  78. γ-Glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney
  79. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models
  80. Mechanisms Controlling Sensitivity to Platinum Complexes: Role of p53 and DNA Mismatch Repair
  81. Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
  82. Novel 7-Oxyiminomethyl Derivatives of Camptothecin with Potent in Vitro and in Vivo Antitumor Activity
  83. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs
  84. Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin
  85. Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy
  86. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line
  87. Novel 7-Substituted Camptothecins with Potent Antitumor Activity
  88. Bcl-2 phosphorylation in a human breast carcinoma xenograft: a common event in response to effective DNA-damaging drugs
  89. Molecular mechanisms of resistance to taxanes and therapeutic implications
  90. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts
  91. Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to Taxol
  92. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
  93. Molecular Mechanisms Controlling Sensitivity to Toxic Metal Ions in Yeast
  94. Role of apoptotic response in cellular resistance to cytotoxic agents
  95. Cisplatin analogues with sulfur donor ligands. (Ethylenediamine)platinum(II) complexes with ligands possessing a sulfinyl or sulfanyl group linked to an anionic oxygen donor atom. Reactivity and cytotoxicity
  96. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types
  97. Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells
  98. The role of glutathione in combination with cisplatin in the treatment of ovarian cancer
  99. Modulation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor
  100. Genetic Manipulation of Yeast to Identify Genes Involved in Regulation of Chemosensitivity